LBRX
LB PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$38.81
+5.63%Oct 6, 2026, 12:00 UTC
LB Pharmaceuticals announced it will host an in-person and virtual R&D Day on October 27, 2026, focused on advancing LB-102 for schizophrenia treatment.
Source:Sep 15, 2026, 12:07 UTC
LB Pharmaceuticals Inc appointed Susan G. Kozauer, M.D. as Chief Medical Officer effective September 14, 2026.
Sep 3, 2026, 12:08 UTC
LB Pharmaceuticals Inc. appointed Joseph M. Miller as Chief Financial Officer, effective September 2, 2026, with an annual base salary of $530,000 and a target bonus of 40% of base salary.
Aug 11, 2026, 00:00 UTC
LB Pharmaceuticals Inc reported a net loss of $51.6 million for Q2 2026, with diluted EPS of -$1.71, and cash and marketable securities of $327.8 million as of June 30, 2026.
Jul 29, 2026, 12:00 UTC
LB Pharmaceuticals Inc entered into a securities purchase agreement to sell shares of common stock and pre-funded warrants to institutional investors in a private placement, raising $150 million.
Source: